

MEMORANDUM OF MEETING

between the Food and Drug Administration and  
the Pharmaceutical Research and Manufacturers Association

August 19, 2002  
1615 L Street, NW  
Suite 1260  
Washington, DC

1/13/03 13:13:10

*Attendees:*

*PhRMA*

Alan Goldhammer, PhRMA and members of the PhRMA Bar Code Task Group

*FDA*

Thomas McGinnis, Office of Policy, Planning, and Legislation  
Erica Keys, Office of the Chief Counsel  
Jerry Phillips, Center for Drug Evaluation and Research  
Mary Gross, Center for Drug Evaluation and Research

The focus of the meeting was to give FDA participants the industry perspective on bar codes, the current use of the NDC number within the EAN/UCC system, current use of bar codes by pharmaceutical firms, types of bar codes available, and difficulties encountered by member firms in the bar coding operations. Industry representatives suggested that the main reason bar codes have not appeared on many unit dose tablets and capsules to date was that there has not been much demand for it. If the demand existed the industry might be able to add not only NDC number in bar code format, but also the lot number and expiration date.

FDA explained that its goal and that of Secretary Thompson was to increase patient safety and that one way to accomplish this was through the use of barcodes.

PhRMA encouraged FDA to consider both current technologies when developing a proposed rule and to maintain flexibility for the industry. The use of bar codes is one method of inventory control besides patient safety.

PhRMA presented samples from Pfizer showing the difference between two possible bar coding approaches. There was a presentation of possible small package configurations; some aspects of the presentation assumed possible regulatory relief from current FDA labeling requirements to provide adequate room for the bar code, drug name, and dosage strength. However, PhRMA indicated that it did not believe that the data supported inclusion of lot number and expiration date information in a bar code at the point of administration, although the information might be helpful at pharmacies.

O2N-D2D4

MM 1

PhRMA stated that its goal is to increase patient safety and alleviate the otherwise-avoidable mistakes that are occurring through the flexible application of innovative technology.